Effect of Combinations of Mycobacteriophages and Drugs against Mycobacterium Spp.
phage therapy; mycobacteriophages; combination therapies
Abstract
The emergence of multidrug-resistant tuberculosis (MDR-TB) is a matter of global concern. The use of mycobacteriophages alone or in combination with antibiotics could be used as an alternative approach to treat drug-resistant Mycobacteria. The aim of the study was the evaluation of the effect of an isolated mycobacteriophage in combination with Isoniazid, Rifampicin, Streptomycin, and Ampicillin against Mycobacterium tuberculosis and Mycobacterium smegmatis. Determination of the MIC of the above drugs for each strain was done by the standard tube dilution method. Further, the inhibitory effect of varying drug concentrations in combination with different dilutions of the mycobacteriophage was studied. The growth inhibition pattern for both the organisms was also studied in the presence of different dilutions of mycobacteriophage by turbidometric and resazurin dye reduction method. The killing pattern of drugs, at concentrations below the MIC, when combined with mycobacteriophage, was determined. The phage induced lysis of bacteria assisted in decreasing the inhibitory concentration of the drugs.
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
URL: https://www.journalofscience.org/index.php/GJSFR/article/view/2576
References
Stephen Abedon, Sarah Kuhl, Bob Blasdel, Elizabeth Kutter (2011) Phage treatment of human infections. 1(2), 66-85. https://doi.org/10.4161/bact.1.2
Stephen Abedon, Cameron Thomas-Abedon (2010) Phage therapy pharmacology. 11(1), 28-47. https://doi.org/10.2174/138920110790725410
Suhail Ahmad (2010) New approaches in the diagnosis and treatment of latent tuberculosis infection. 11(1), 169-185. https://doi.org/10.1186/1465-9921-11-169
J. Caminero, G. Sotgiu, A. Zumla, G. Migliori (2010) Best drug treatment for multidrugresistant and extensively drug-resistant tuberculosis. Lancet Infect. 10, 621-629. https://doi.org/10.1016/s1473-3099(10)70139-0
R. Dedrick, C. Guerrero-Bustamante, R. Garlena, D. Russell, K. Ford, K. Harris, K. Gilmour, J. Soothill, D. Jacobs-Sera, R. Schooley, G. Hatfull, H. Spencer (2019) Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. 25(5), 730-733. https://doi.org/10.1038/s41591-019-0437-z
J. Dinnes, J. Deeks, H. Kunst, A. Gibson, E. Cummins, N. Waugh, F. Drobniewski, A. Lalvani (2007) A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol. 11(3), 1-196. https://doi.org/10.3310/hta11030
V. Gondil, S. Chhibber (2018) Exploring potential of phage therapy for tuberculosis using model organism. Biomed. Biotechnol. Res. 2, 9-15. https://doi.org/10.4103/bbrj.bbrj_93_17
Shuliang Guo, A. Zhi (2012) Phage in the diagnosis and treatment of tuberculosis. 17(7), 2691. https://doi.org/10.2741/4080
Graham Hatfull (2014) Mycobacteriophages: Windows into Tuberculosis. 10(3), e1003953. https://doi.org/10.1371/journal.ppat.1003953
G. Hatfull (2012) The Secret Lives of Mycobacteriophages. 82, 179288. https://doi.org/10.1016/b978-0-12-394621-8.00015-7
V. Leimane, V. Riekstina, T. Holtz, E. Zarovska, V. Skripconoka, L. Thorpe, K. Laserson, C. Wells (2005) Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. 365(9456), 318-326. https://doi.org/10.1016/S0140-s6736(05)17786-1
Derek Lin, Britt Koskella, Henry Lin (2017) Phage therapy: An alternative to antibiotics in the age of multidrug-resistance. World J. Gastrointest. Pharmacol. 8(3), 162. https://doi.org/10.4292/wjgpt.v8.i3.162
P. Li, L. Yong-ai, C. Bao wen, L. Youlun, S. Xiaobing, S. Cheng, W. Guozhi (2009) Therapeutic effect of bacteriophage D29 in the treatment for guinea pigs infected with sensitive strain of Mycobacterium tuberculosis.
S. Matsuzaki, M. Rashel, J. Uchiyama, S. Sakurai, T. Ujihara, M. Kuroda, M. Ikeuchi (2005) Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. 11(5), 211-219. https://doi.org/10.1007/s10156-005-0408-9
C. Merril, B. Biswas, R. Carlton, N. Jensen, G. Creed, S. Zullo, S. Adhya (1996) Longcirculating bacteriophage as antibacterial agents. 93(8), 3188-3192. https://doi.org/10.1073/pnas.93.8.3188
J. Pereira, H. David, N. Rastogi (1983) Isolation and partial characterization of temperaturesensitive mutants of the mycobacteriophage D29. 134, 33-49. https://doi.org/10.1016/S0769-2617(83)80040-9
W. Pope, C. Ferreira, D. Jacobs-Sera, R. Benjamin, Davis, R. A. J.De Jong (2011) Cluster K Mycobacteriophages: Insights into the Evolutionary Origins of Mycobacteriophage TM4. 6(10), e26750. https://doi.org/10.1371/journal.pone.0026750
Sourabh Samaddar, Rajdeep Grewal, Saptarshi Sinha, Shrestha Ghosh, Soumen Roy, Sujoy Das Gupta (2016) Dynamics of Mycobacteriophage-Mycobacterial Host Interaction: Evidence for Secondary Mechanisms for Host Lethality. Appl. Environ. 82(1), 124-133. https://doi.org/10.1128/aem.02700-15
Rajitha Satish, Anita Desouza (2019) Study of characteristics of mycobacteriophage - A novel tool to treat Mycobacterium spp. 8(2), 170. https://doi.org/10.4103/ijmy.ijmy_42_19
R. Satish, A. Desouza (2018) Isolation of mycobacteriophage: Novel tool to treat Mycobacterium spp. Int. J. Sci. Res. Biol. 5, 46-50. https://doi.org/10.26438/ijsrbs/v5i2.4650
N. Shah, A. Wright, G. Bai, L. Barrera, F. Boulahbal, N. Martín-Casabona, J. Cegielski (2007) Worldwide Emergence of Extensively Drug-resistant Tuberculosis. 13(3), 380-387. https://doi.org/10.3201/eid1303.061400
Alexander Sulakvelidze, Zemphira Alavidze, J. Morris (2001) Bacteriophage Therapy. Antimicrob. 45(3), 649-659. https://doi.org/10.1128/aac.45.3.649-659.2001
Y. Tanji (2005) Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. 100(3), 280-287. https://doi.org/10.1263/jbb.100.280
Y. Tanji (2004) Toward rational control of Escherichia coli O157: H7 by a phage cocktail. Appl. Microbiol. 64(2), 270-274. https://doi.org/10.1007/s00253-003-1438-9
Christal Vitiello, Carl Merril, Sankar Adhya (2005) An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. 114(1-2), 101-103. https://doi.org/10.1016/j.virusres.2005.05.014
Published
2019-12-05
Issue
Section
License
Copyright (c) 2019 Authors and Global Journals Private Limited

This work is licensed under a Creative Commons Attribution 4.0 International License.